CYP26A1 Is a Novel Cancer Biomarker of Pancreatic Carcinoma: Evidence from Integration Analysis and In Vitro Experiments

Figure 7

CYP26A1 might be associated with the sensitivity of chemotherapy and immunotherapy. Notes: (a) the correlation between CYP26A1 and multiple immune checkpoints. (b) TIDE analysis showed that the immunotherapy responders had a lower CYP26A1 level than non_responders. (c)–(e) GDSC analysis was performed to explore the correlation between IC50 of chemotherapeutic drugs and CYP26A1 expression. (f, g) Knockdown of CYP26A1 could decrease the sensitivity of PC cells to gemcitabine.

(a)

(b)

(c)

(d)

(e)

(f)

(g)